Kailera Therapeutics KLRA Phase 1 Data: Tri-Agonist Shows Up To 16% Weight Loss
Kailera Therapeutics reported Phase 1 data for its tri-agonist, showing up to 16.0% mean weight loss at 12 mg over 12 weeks, with safety consistent with GLP-1s.
Kailera reported Phase 1 data showing ribupatide had similar exposure across injection sites. 0% mean weight loss at 12 mg over 12 weeks in Phase 1, with safety consistent with GLP-1s. Material Details Context by AI Analyst This is incremental but supporti…